SLC5A2 and hydrops fetalis: Patients under SGLT2 experienced a symptomatic improvement, with a 23.8% reduction in patients in NYHA functional class III at 6 month follow-up, while patients in the control group had a symptomatic deterioration, which is in line with both EMPA-TROPISM [14] and DEFINE-HF [26] that revealed a quality-of-life improvement assessed by the Kansas City Cardiomyopathy Questionnaire.